NCT04012307View on ClinicalTrials.gov

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

August 13, 2019

Study Completion Date

August 14, 2019

Conditions
Bioequivalence
Interventions
DRUG

Candesartan Cilexetil 32mg

Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.

DRUG

Atacand® PROTECT

Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.

Trial Locations (1)

H3P 3P1

Altasciences Company Inc., Mount Royal

All Listed Sponsors
collaborator

Altasciences Company Inc.

INDUSTRY

lead

Pharmtechnology LLC

INDUSTRY

NCT04012307 - The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions | Biotech Hunter | Biotech Hunter